Use of glyburide to treat gestational diabetes is linked to adverse outcomes in babies, study findsBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1709 (Published 31 March 2015) Cite this as: BMJ 2015;350:h1709
- Jacqui Wise
Babies born to mothers treated with the sulfonylurea drug glyburide (glibenclamide) for gestational diabetes mellitus are more likely to experience adverse outcomes than those whose mothers are treated with insulin, research published in JAMA Pediatrics has found.1 Although the oral hypoglycaemic agent does not have marketing authorisation for use in pregnancy, it is used increasingly widely.
The retrospective cohort study found that glyburide was associated with a higher risk for newborns to be admitted to a neonatal intensive care unit, to have respiratory distress, hypoglycaemia, or birth injury, or to be large for their gestational age when compared with infants born to women treated …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial